Media & Resources

A statement from Dr. Seth Berkley of the International AIDS Vaccine Initiative NEW YORK, NY – May 15, 2009 – World AIDS Vaccine Day, May 18, marks the occasion in 1997 when U.S. President Bill Clinton challenged researchers to come up with an AIDS vaccine within the following decade, stating that such a vaccine was…

NEW YORK, May 5, 2009─Dr. C. Richter (Rick) King, former Senior Vice President of Research at GenVec, Inc., has joined the International AIDS Vaccine Initiative (IAVI) as Vice President of Vaccine Discovery.  In his new position, Dr. King will play a vital role in leading and managing IAVI’s global vaccine discovery initiatives in support of…

NEW YORK, NY, April 30, 2009 — TIME magazine has named Dr. Seth Berkley, President and CEO of the International AIDS Vaccine Initiative (IAVI), one of this year’s “100 Most Influential People in the World.” Berkley, a medical doctor and infectious disease epidemiologist, is joined by world leaders, icons, thinkers, visionaries and others whose ideas…

This World AIDS Day comes at a time of remarkable progress in biomedical HIV prevention. In late November, researchers announced that in a Phase III trial, a daily dose of an antiretroviral (ARV) treatment taken as prophylaxis reduced HIV infection in men at high risk by 44%. Earlier, a vaginal microbicide gel reduced HIV infection…

New York, November 30, 2010— The International AIDS Vaccine Initiative (IAVI) is pleased to announce the appointment of Jane Waterman to its management team as Executive Director, Europe. Waterman, who will be based in IAVI’s Amsterdam office, will direct IAVI’s operations in Europe. Leading a team of 13 staff members, she will oversee activities including…

The International AIDS Vaccine Initiative (IAVI) welcomes the news that in a Phase III clinical pre-exposure prophylaxis (PrEP) trial, daily dosing with a combination of two antiretroviral medications reduced the risk of HIV acquisition in men who have sex with men and are at high risk of HIV infection. In the trial–known as the Pre-Exposure…

NineSigma and IAVI Partner to Find Novel Solutions to Support the Development of an AIDS Vaccine The International AIDS Vaccine Initiative (IAVI) will utilize NineSigma’s proven Open Innovation approach to find breakthrough protein-stabilizing solutions that can be used to create an effective AIDS vaccine. CLEVELAND, Ohio – October 26, 2010 – NineSigma, the leading provider…

New York, October 22, 2010 —The International AIDS Vaccine Initiative (IAVI) today announced the start of a Phase I clinical trial to evaluate the safety and immunogenicity of two preventive AIDS vaccine candidates. The trial, called B003/IPCAVD-004, is the first to test these vaccine candidates in a prime-boost combination, a regimen in which vaccines are given…